

Gian Paolo Dagrada

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5622741/publications.pdf>

Version: 2024-02-01

59
papers

3,297
citations

147566
31
h-index

149479
56
g-index

60
all docs

60
docs citations

60
times ranked

4385
citing authors

#	ARTICLE	IF	CITATIONS
1	The Leydig cell tumour Scaled Score (LeSS): a method to distinguish benign from malignant cases, with additional correlation with <i>MDM2</i> and <i>CDK4</i> amplification. <i>Histopathology</i> , 2021, 78, 290-299.	1.6	21
2	Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: A case-series analysis within the Italian Rare Cancer Network. <i>Cancer</i> , 2021, 127, 569-576.	2.0	24
3	Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma. <i>Modern Pathology</i> , 2020, 33, 217-227.	2.9	15
4	Dermatofibrosarcoma protuberans in children and adolescents: The European Paediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005). <i>Pediatric Blood and Cancer</i> , 2020, 67, e28351.	0.8	11
5	Next-Generation Sequencing Approaches for the Identification of Pathognomonic Fusion Transcripts in Sarcomas: The Experience of the Italian ACC Sarcoma Working Group. <i>Frontiers in Oncology</i> , 2020, 10, 489.	1.3	38
6	Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1252-1262.	5.1	57
7	NR4A3 fusion proteins trigger an axon guidance switch that marks the difference between EWSR1 and TAF15 translocated extraskeletal myxoid chondrosarcomas. <i>Journal of Pathology</i> , 2019, 249, 90-101.	2.1	27
8	Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study. <i>European Journal of Cancer</i> , 2019, 106, 225-233.	1.3	32
9	The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelial-mesenchymal transition, and immune response. <i>Cancer Communications</i> , 2018, 38, 1-14.	3.7	25
10	Self-Assembled Nanomicelles as Curcumin Drug Delivery Vehicles: Impact on Solitary Fibrous Tumor Cell Protein Expression and Viability. <i>Molecular Pharmaceutics</i> , 2018, 15, 4689-4701.	2.3	11
11	Identification of an Actionable Mutation of KIT in a Case of Extraskeletal Myxoid Chondrosarcoma. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1855.	1.8	4
12	Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour. <i>European Journal of Cancer</i> , 2017, 76, 84-92.	1.3	26
13	<i>HSPA8</i> as a novel fusion partner of <i>NR4A3</i> in extraskeletal myxoid chondrosarcoma. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 582-586.	1.5	38
14	Mechanism of action of trabectedin in desmoplastic small round cell tumor cells. <i>BMC Cancer</i> , 2017, 17, 107.	1.1	11
15	Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment. <i>Journal of Investigative Dermatology</i> , 2017, 137, 484-493.	0.3	29
16	Identification of SRF-E2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue. <i>Oncotarget</i> , 2017, 8, 60036-60045.	0.8	17
17	Absence of ALK and MET alterations in head and neck sarcomatoid carcinoma. <i>Oral Oncology</i> , 2016, 58, e4-e5.	0.8	3
18	Evolution of Dermatofibrosarcoma Protuberans to DFSP-Derived Fibrosarcoma: An Event Marked by Epithelial-Mesenchymal Transition-like Process and 22q Loss. <i>Molecular Cancer Research</i> , 2016, 14, 820-829.	1.5	25

#	ARTICLE	IF	CITATIONS
19	Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database. <i>Annals of Surgical Oncology</i> , 2016, 23, 2735-2744.	0.7	56
20	A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact. <i>European Journal of Cancer</i> , 2016, 69, 158-165.	1.3	66
21	Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers. <i>Head and Neck</i> , 2016, 38, 724-731.	0.9	104
22	Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP). <i>Clinical Cancer Research</i> , 2016, 22, 837-846.	3.2	78
23	Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases. <i>Oncotarget</i> , 2016, 7, 47848-47863.	0.8	43
24	Epithelioid peritoneal mesothelioma: a hybrid phenotype within a mesenchymal-epithelial/epithelial-mesenchymal transition framework. <i>Oncotarget</i> , 2016, 7, 75503-75517.	0.8	16
25	Myogenic Differentiation and Histologic Grading Are Major Prognostic Determinants in Retroperitoneal Liposarcoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 383-393.	2.1	101
26	Solitary fibrous tumors: loss of chimeric protein expression and genomic instability mark dedifferentiation. <i>Modern Pathology</i> , 2015, 28, 1074-1083.	2.9	67
27	Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy. <i>British Journal of Cancer</i> , 2014, 111, 1350-1362.	2.9	21
28	Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies. <i>Neuro-Oncology</i> , 2014, 16, 72-80.	0.6	13
29	Activity of sunitinib in extraskeletal myxoid chondrosarcoma. <i>European Journal of Cancer</i> , 2014, 50, 1657-1664.	1.3	74
30	Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour. <i>European Journal of Cancer</i> , 2014, 50, 3021-3028.	1.3	50
31	Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study. <i>Clinical Sarcoma Research</i> , 2013, 3, 16.	2.3	34
32	Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib. <i>Clinical Sarcoma Research</i> , 2012, 2, 22.	2.3	27
33	A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. <i>Leukemia</i> , 2012, 26, 349-355.	3.3	298
34	The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 765-774.	1.5	59
35	Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1703-1707.	1.1	39
36	Heterogeneity in the Prognostic Significance of 12p Deletion and Chromosome 5 Amplification in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2011, 29, e37-e39.	0.8	12

#	ARTICLE	IF	CITATIONS
37	Mapping of Chromosome 1p Deletions in Myeloma Identifies <i>FAM46C</i> at 1p12 and <i>CDKN2C</i> at 1p32.3 as Being Genes in Regions Associated with Adverse Survival. <i>Clinical Cancer Research</i> , 2011, 17, 7776-7784.	3.2	147
38	The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. <i>Haematologica</i> , 2010, 95, 1221-1225.	1.7	84
39	A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. <i>Blood</i> , 2010, 116, e56-e65.	0.6	315
40	Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case. <i>Haematologica</i> , 2009, 94, 1024-1028.	1.7	47
41	Frequent upregulation of <i>MYC</i> in plasma cell leukemia. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 624-636.	1.5	65
42	Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context. <i>Haematologica</i> , 2009, 94, 1708-1713.	1.7	68
43	TRK-A, HER-2/neu, and KIT Expression/Activation Profiles in Salivary Gland Carcinoma. <i>Translational Oncology</i> , 2008, 1, 121-128.	1.7	15
44	Deletions of <i>CDKN2C</i> in Multiple Myeloma: Biological and Clinical Implications. <i>Clinical Cancer Research</i> , 2008, 14, 6033-6041.	3.2	88
45	Gene mapping and expression analysis of 16q loss of heterozygosity identifies <i>WWOX</i> and <i>CYLD</i> as being important in determining clinical outcome in multiple myeloma. <i>Blood</i> , 2007, 110, 3291-3300.	0.6	133
46	Molecular and Cytogenetic Subgroups of Oropharyngeal Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2006, 12, 6643-6651.	3.2	159
47	PDGFR [±] , PDGFR ² and KIT expression/activation in conventional chondrosarcoma. <i>Journal of Pathology</i> , 2006, 208, 615-623.	2.1	48
48	Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. <i>Leukemia</i> , 2006, 20, 1610-1617.	3.3	141
49	Molecular and Biochemical Analyses of Platelet-Derived Growth Factor Receptor (PDGFR) B, PDGFRA, and KIT Receptors in Chordomas. <i>Clinical Cancer Research</i> , 2006, 12, 6920-6928.	3.2	135
50	Herceptin [®] plus chemotherapy in relapsed and/or metastatic salivary gland cancer. <i>Oral Oncology</i> , 2005, 41, 97-98.	0.8	23
51	9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for kit and platelet-derived growth factor receptor [±] gene alterations. <i>Cancer</i> , 2005, 104, 159-169.	2.0	56
52	Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. <i>Histopathology</i> , 2004, 44, 301-302.	1.6	34
53	Molecular cytogenetic characterization of proximal-type epithelioid sarcoma. <i>Genes Chromosomes and Cancer</i> , 2004, 41, 283-290.	1.5	67
54	HER-2/neu Assessment in Primary Chemotherapy Treated Breast Carcinoma: No Evidence of Gene Profile Changing. <i>Breast Cancer Research and Treatment</i> , 2003, 80, 207-214.	1.1	23

#	ARTICLE	IF	CITATIONS
55	Evidence of Neural Differentiation in a Case of Post-therapy Primitive Neuroectodermal Tumor/Ewing Sarcoma of Bone. <i>American Journal of Surgical Pathology</i> , 2003, 27, 1161-1166.	2.1	27
56	Immunophenotypic and genotypic analysis of a case of primary peripheral primitive neuroectodermal tumour (pPNET) of the urinary bladder. <i>Histopathology</i> , 2002, 40, 108-109.	1.6	16
57	Detection of bladder cancer by multitarget multicolour FISH: comparative analysis on archival cytology and paraffin-embedded tissue. <i>Cytopathology</i> , 2002, 13, 317-325.	0.4	7
58	Opposite deletions/duplications of the X chromosome: two novel reciprocal rearrangements. <i>European Journal of Human Genetics</i> , 2000, 8, 63-70.	1.4	16
59	SYT-SSX Fusion Transcripts and Epithelial Differentiation in Synovial Sarcoma. <i>Diagnostic Molecular Pathology</i> , 2000, 9, 234.	2.1	8